Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that Phase I/II clinical trials are underway for...
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that Phase I/II clinical trials are underway for...
Easton Pharmaceutical Co., Ltd (SHA: 688513) announced that its generic version of remimazolam besylate has...
Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that the first subject has been dosed in...
Kexing Biopharm (SHA: 688136) today announced a strategic cooperation agreement with Chengdu Easton Biopharmaceuticals Co.,...
Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval...
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced that it has received separate marketing...
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced receiving Abbreviated New Drug Application (ANDA)...